Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They currently have a $50.00 target price on the biotechnology company’s stock.
A number of other equities research analysts have also weighed in on ATNM. HSBC began coverage on Actinium Pharmaceuticals in a research report on Wednesday. They set a “buy” rating and a $11.60 target price for the company. StockNews.com raised Actinium Pharmaceuticals to a “sell” rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Actinium Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $28.32.
Actinium Pharmaceuticals Price Performance
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. UBS Group AG boosted its position in shares of Actinium Pharmaceuticals by 76.2% during the fourth quarter. UBS Group AG now owns 3,235 shares of the biotechnology company’s stock worth $34,000 after buying an additional 1,399 shares during the period. Quent Capital LLC purchased a new position in shares of Actinium Pharmaceuticals during the second quarter worth $37,000. Royal Bank of Canada boosted its position in shares of Actinium Pharmaceuticals by 38.5% during the second quarter. Royal Bank of Canada now owns 6,734 shares of the biotechnology company’s stock worth $49,000 after buying an additional 1,871 shares during the period. California State Teachers Retirement System acquired a new position in Actinium Pharmaceuticals during the 2nd quarter worth $64,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Actinium Pharmaceuticals during the 2nd quarter worth $83,000. 22.38% of the stock is currently owned by hedge funds and other institutional investors.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.
- Five stocks we like better than Actinium Pharmaceuticals
- Airline Stocks – Top Airline Stocks to Buy Now
- The Best 5 Small Cap AI Companies to Buy Now
- What is the FTSE 100 index?
- Miso Robotics Stock: Is an IPO Coming Soon?
- How to Buy Cheap Stocks Step by Step
- 3 Stocks to Play the Easing Food Supply Chain
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.